These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8198019)

  • 1. Updated clinical safety experience with fluvastatin.
    Jokubaitis LA
    Am J Cardiol; 1994 May; 73(14):18D-24D. PubMed ID: 8198019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of the biopharmaceutical properties of fluvastatin.
    Deslypere JP
    Am J Cardiol; 1994 May; 73(14):12D-17D. PubMed ID: 8198018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of fluvastatin in cardiovascular risk management.
    McDonald KJ; Jardine AG
    Expert Opin Pharmacother; 2008 Jun; 9(8):1407-14. PubMed ID: 18473714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
    Dujovne CA; Davidson MH
    Am J Med; 1994 Jun; 96(6A):37S-40S. PubMed ID: 8017465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia.
    Sabia H; Prasad P; Smith HT; Stoltz RR; Rothenberg P
    J Cardiovasc Pharmacol; 2001 May; 37(5):502-11. PubMed ID: 11336101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
    Plosker GL; Wagstaff AJ
    Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvastatin for lowering cholesterol.
    Med Lett Drugs Ther; 1994 May; 36(923):45-6. PubMed ID: 8177137
    [No Abstract]   [Full Text] [Related]  

  • 8. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
    Goldberg RB; Roth D
    Am J Cardiol; 1995 Jul; 76(2):107A-109A. PubMed ID: 7604782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
    Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
    Jacobson TA; Amorosa LF
    Am J Cardiol; 1994 May; 73(14):25D-29D. PubMed ID: 8198020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
    Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
    Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluvastatin, rhabdomyolysis, and myotoxicity.
    Murinson BB; Maragakis NJ; Jacobson TA
    Mayo Clin Proc; 2008 Nov; 83(11):1296; author reply 1297. PubMed ID: 18990330
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.
    Smit JW; Wijnne HJ; Schobben F; Sitsen A; de Bruin TW; Erkelens DW
    Am J Cardiol; 1995 Jul; 76(2):89A-96A. PubMed ID: 7604808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvastatin-induced rhabdomyolysis.
    Modi JR; Cratty MS
    Ann Pharmacother; 2002 Dec; 36(12):1870-4. PubMed ID: 12452746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and pharmacology of fluvastatin.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():11-5. PubMed ID: 8729584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
    Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
    Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of fluvastatin.
    Scripture CD; Pieper JA
    Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and pharmacology of fluvastatin.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):11-5. PubMed ID: 19489169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats.
    Sugatani J; Sadamitsu S; Kurosawa M; Ikushiro S; Sakaki T; Ikari A; Miwa M
    Drug Metab Dispos; 2010 Oct; 38(10):1655-64. PubMed ID: 20587623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery.
    Voûte MT; Winkel TA; Poldermans D
    Expert Opin Drug Saf; 2010 Sep; 9(5):793-800. PubMed ID: 20557267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.